Pushing the Envelope: Advancement of ADCs Outside of Oncology

Area of Science:

• Biotechnology
• Pharmacology
• Drug Discovery

Background:

• Antibody-drug conjugates (ADCs) are primarily developed for oncology, utilizing cytotoxic payloads to target cancer cells.
• The application of ADCs is expanding to non-oncology indications by modulating pathogenic cellular activity.

Purpose of the Study:

• To summarize existing ADCs for non-oncology applications.
• To review diverse payload mechanisms beyond simple cell killing.
• To highlight the progression from in vitro studies to clinical trials for non-oncology ADCs.

Main Methods:

• Literature review of ADCs described for non-oncology applications.
• Analysis of payload mechanisms and therapeutic targets.
• Examination of study stages, from in vitro proof-of-concept to clinical trials.

Main Results:

• Several ADCs for non-oncology indications have been reported.
• Payload mechanisms extend beyond cytotoxicity, including modulation of cellular pathways.
• Development spans early research to clinical investigations.

Conclusions:

• ADC technology offers promising therapeutic strategies for non-oncology diseases.
• The scope of ADC applications is expected to broaden significantly.
• Further development of ADCs for non-oncology indications is anticipated.